Engineers Gate Manager LP Bio N Tech Se Transaction History

Engineers Gate Manager LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $538,894 - $689,846	6,706 New	6,706 $538,000
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $674,643 - $836,717	7,421 New	7,421 $783,000
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $436,104 - $546,757	-3,558 Reduced 58.81%	2,492 $310,000
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $716,501 - $1.13 Million	6,050 New	6,050 $908,000
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $610,210 - $922,074	4,951 New	4,951 $738,000
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $246,566 - $452,803	-1,953 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $423,097 - $708,001	1,953 New	1,953 $503,000
Q1 2021 May 17, 2021	SELL	$85.73 - $119.5 $1.18 Million - $1.65 Million	-13,800 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$72.71 - $129.54 $1 Million - $1.79 Million	13,800 New	13,800 $1.13 Million

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.